vs

Side-by-side financial comparison of OPENLANE, Inc. (OPLN) and Royalty Pharma plc (RPRX). Click either name above to swap in a different company.

Royalty Pharma plc is the larger business by last-quarter revenue ($622.0M vs $494.3M, roughly 1.3× OPENLANE, Inc.). Royalty Pharma plc runs the higher net margin — 34.4% vs 12.0%, a 22.4% gap on every dollar of revenue. On growth, OPENLANE, Inc. posted the faster year-over-year revenue change (8.6% vs 4.8%). Over the past eight quarters, OPENLANE, Inc.'s revenue compounded faster (7.2% CAGR vs 4.6%).

OPENLANE, Inc. operates a leading global digital wholesale automotive marketplace platform. It connects vehicle sellers including dealerships, fleet operators, financial institutions, and rental firms with qualified professional buyers, facilitating efficient, transparent transactions for used, off-lease, and repossessed vehicles across North America, Europe, and key global markets.

Acceleron Pharma, Inc. is an American clinical stage biopharmaceutical company based in Cambridge, Massachusetts with a broad focus on developing medicines that regulate the transforming growth factor beta (TGF-β) superfamily of proteins, which play fundamental roles in the growth and repair of cells and tissues such as red blood cells, muscle, bone, and blood vessels.

OPLN vs RPRX — Head-to-Head

Bigger by revenue
RPRX
RPRX
1.3× larger
RPRX
$622.0M
$494.3M
OPLN
Growing faster (revenue YoY)
OPLN
OPLN
+3.9% gap
OPLN
8.6%
4.8%
RPRX
Higher net margin
RPRX
RPRX
22.4% more per $
RPRX
34.4%
12.0%
OPLN
Faster 2-yr revenue CAGR
OPLN
OPLN
Annualised
OPLN
7.2%
4.6%
RPRX

Income Statement — Q4 FY2025 vs Q4 FY2025

Metric
OPLN
OPLN
RPRX
RPRX
Revenue
$494.3M
$622.0M
Net Profit
$59.5M
$214.2M
Gross Margin
Operating Margin
8.6%
62.4%
Net Margin
12.0%
34.4%
Revenue YoY
8.6%
4.8%
Net Profit YoY
13.8%
2.9%
EPS (diluted)
$-1.54
$0.49

Green = leading value per metric. Periods may differ when fiscal calendars don't align.

8-Quarter Revenue & Profit Trend

Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.

Revenue
OPLN
OPLN
RPRX
RPRX
Q4 25
$494.3M
$622.0M
Q3 25
$498.4M
$609.3M
Q2 25
$481.7M
$578.7M
Q1 25
$460.1M
$568.2M
Q4 24
$455.0M
$593.6M
Q3 24
$459.8M
$564.7M
Q2 24
$443.8M
$537.3M
Q1 24
$429.9M
$568.0M
Net Profit
OPLN
OPLN
RPRX
RPRX
Q4 25
$59.5M
$214.2M
Q3 25
$47.9M
$288.2M
Q2 25
$33.4M
$30.2M
Q1 25
$36.9M
$238.3M
Q4 24
$52.3M
$208.2M
Q3 24
$28.4M
$544.0M
Q2 24
$10.7M
$102.0M
Q1 24
$18.5M
$4.8M
Operating Margin
OPLN
OPLN
RPRX
RPRX
Q4 25
8.6%
62.4%
Q3 25
11.0%
70.1%
Q2 25
9.8%
36.3%
Q1 25
11.2%
94.0%
Q4 24
17.4%
60.9%
Q3 24
9.2%
Q2 24
5.4%
50.2%
Q1 24
8.6%
-13.0%
Net Margin
OPLN
OPLN
RPRX
RPRX
Q4 25
12.0%
34.4%
Q3 25
9.6%
47.3%
Q2 25
6.9%
5.2%
Q1 25
8.0%
41.9%
Q4 24
11.5%
35.1%
Q3 24
6.2%
96.3%
Q2 24
2.4%
19.0%
Q1 24
4.3%
0.8%
EPS (diluted)
OPLN
OPLN
RPRX
RPRX
Q4 25
$-1.54
$0.49
Q3 25
$0.25
$0.67
Q2 25
$0.15
$0.07
Q1 25
$0.18
$0.55
Q4 24
$0.28
$0.46
Q3 24
$0.12
$1.21
Q2 24
$0.00
$0.23
Q1 24
$0.05
$0.01

Balance Sheet & Financial Strength

Snapshot of each company's liquidity, leverage and book value from the latest quarter.

Metric
OPLN
OPLN
RPRX
RPRX
Cash + ST InvestmentsLiquidity on hand
$141.5M
$618.7M
Total DebtLower is stronger
$550.0M
$9.0B
Stockholders' EquityBook value
$1.2B
$9.7B
Total Assets
$4.7B
$19.6B
Debt / EquityLower = less leverage
0.44×
0.92×

8-quarter trend — quarters aligned by calendar period.

Cash + ST Investments
OPLN
OPLN
RPRX
RPRX
Q4 25
$141.5M
$618.7M
Q3 25
$119.3M
$938.9M
Q2 25
$119.1M
$631.9M
Q1 25
$220.5M
$1.1B
Q4 24
$143.0M
$929.0M
Q3 24
$132.1M
$950.1M
Q2 24
$60.9M
$1.8B
Q1 24
$105.2M
$843.0M
Total Debt
OPLN
OPLN
RPRX
RPRX
Q4 25
$550.0M
$9.0B
Q3 25
$8.9B
Q2 25
$8.0B
Q1 25
$7.6B
Q4 24
$230.7M
$7.6B
Q3 24
$7.6B
Q2 24
$7.6B
Q1 24
$6.1B
Stockholders' Equity
OPLN
OPLN
RPRX
RPRX
Q4 25
$1.2B
$9.7B
Q3 25
$1.4B
$9.6B
Q2 25
$1.4B
$9.5B
Q1 25
$1.4B
$9.8B
Q4 24
$1.3B
$10.3B
Q3 24
$1.3B
$10.3B
Q2 24
$1.3B
$9.8B
Q1 24
$1.3B
$9.9B
Total Assets
OPLN
OPLN
RPRX
RPRX
Q4 25
$4.7B
$19.6B
Q3 25
$4.8B
$19.3B
Q2 25
$4.6B
$18.3B
Q1 25
$4.8B
$17.6B
Q4 24
$4.6B
$18.2B
Q3 24
$4.6B
$18.0B
Q2 24
$4.6B
$17.7B
Q1 24
$4.8B
$16.1B
Debt / Equity
OPLN
OPLN
RPRX
RPRX
Q4 25
0.44×
0.92×
Q3 25
0.93×
Q2 25
0.84×
Q1 25
0.78×
Q4 24
0.17×
0.74×
Q3 24
0.74×
Q2 24
0.78×
Q1 24
0.62×

Cash Flow & Capital Efficiency

How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.

Metric
OPLN
OPLN
RPRX
RPRX
Operating Cash FlowLast quarter
$125.5M
$827.1M
Free Cash FlowOCF − Capex
$110.8M
FCF MarginFCF / Revenue
22.4%
Capex IntensityCapex / Revenue
3.0%
Cash ConversionOCF / Net Profit
2.11×
3.86×
TTM Free Cash FlowTrailing 4 quarters
$336.5M

8-quarter trend — quarters aligned by calendar period.

Operating Cash Flow
OPLN
OPLN
RPRX
RPRX
Q4 25
$125.5M
$827.1M
Q3 25
$72.2M
$702.6M
Q2 25
$71.6M
$364.0M
Q1 25
$122.6M
$596.1M
Q4 24
$32.7M
$742.5M
Q3 24
$122.4M
$703.6M
Q2 24
$37.5M
$658.2M
Q1 24
$100.2M
$664.6M
Free Cash Flow
OPLN
OPLN
RPRX
RPRX
Q4 25
$110.8M
Q3 25
$57.6M
Q2 25
$57.4M
Q1 25
$110.7M
Q4 24
$18.7M
Q3 24
$109.3M
Q2 24
$24.5M
Q1 24
$87.3M
FCF Margin
OPLN
OPLN
RPRX
RPRX
Q4 25
22.4%
Q3 25
11.6%
Q2 25
11.9%
Q1 25
24.1%
Q4 24
4.1%
Q3 24
23.8%
Q2 24
5.5%
Q1 24
20.3%
Capex Intensity
OPLN
OPLN
RPRX
RPRX
Q4 25
3.0%
Q3 25
2.9%
Q2 25
2.9%
Q1 25
2.6%
Q4 24
3.1%
Q3 24
2.8%
Q2 24
2.9%
Q1 24
3.0%
Cash Conversion
OPLN
OPLN
RPRX
RPRX
Q4 25
2.11×
3.86×
Q3 25
1.51×
2.44×
Q2 25
2.14×
12.06×
Q1 25
3.32×
2.50×
Q4 24
0.63×
3.57×
Q3 24
4.31×
1.29×
Q2 24
3.50×
6.45×
Q1 24
5.42×
139.10×

Financial Flow Comparison

Revenue → gross profit → operating profit → net profit for each company.

Revenue Breakdown by Segment

OPLN
OPLN

Marketplace$384.7M78%
Finance$109.6M22%

RPRX
RPRX

Financial Royalty Assets$592.4M95%
Royalty Income Other$29.6M5%

Related Comparisons